It is a direct factor Xa inhibitor that demonstrates rapid absorption and a half-life of 12 hours and is 25% renally excreted.27 The results of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial led to apixaban approval.28 In this trial, 18,201 patients with nonvalvular AF and one or more stroke risk factors were randomized to receive either apixaban or warfarin. This evidence concerns the gene F10 and stroke disorder.